Astec LifeSciences
- Market cap
- ₹ 1,480 Cr.
- P/E
- 110.6x
- P/B
- 3.82x
- 52-week range
- 513.4 – 941.75
- ROE
- −25%
- ROCE
- −5%
- Dividend yield
- 0%
- Debt / equity
- 1.15
- Sector
- Fertilizers & Agrochemicals
- Industry
- Pesticides & Agrochemicals
- Listed on
- NSE, BSE
About
Astec LifeSciences Limited is an India-based company, which is engaged in the manufacturing of agrochemical active ingredients (technical), bulk, formulations and intermediate products. The Company undertakes contract development and manufacturing services for a diverse range of agrochemicals. The Company operates through a single segment, namely Agrochemicals. Its product categories include Fungicide, Growth Regulator, Intermediates, Insecticide, and Herbicide. Its products include Azimsulfuron, Halosulfuron, Flutriafol, Rimsulfuron, Transfluthrin, Prothiaconazole, Metalaxyl, Cyproconazole, and Tribenuron methyl. It has a sales mix of both exports and domestic sales. It exports to approximately 17 countries, including the United States and countries across Europe, West Asia, South-East Asia, Latin America and Africa. The Company has approximately nine manufacturing plants, which are located in Maharashtra.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pesticides & Agrochemicals: 33 companies →Astec LifeSciences against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)110.6 against a typical 23.3: pricier than most peers (1st = cheapest).31st of 33
- Sales growth−7.7% against a typical −4.5% from a year earlier.17th of 31
- Share price, 3 months−6.7% against a typical −15.5%.9th of 32
- Size₹ 1,480.5 Cr. market value against a typical ₹ 883.3 Cr. (1st = largest).13th of 31
Latest announcements
Exchange filings and their impact on the company.
- Q2 loss widened to Rs 37.4 cr on falling sales and -27.5% operating margin, keeping full-year deeply loss-making.
Astec LifeSciences reported Q2 FY27 revenue of Rs 72.0 crore, down from Rs 73.7 crore a year ago, with an operating margin of -27.5% and a net loss of Rs 37.4 crore versus Rs 24.4 crore last year. For H1, revenue was Rs 155.6 crore with a loss of Rs 56.1 crore, almost flat YoY. Continued weak sales, high costs and interest burden mean losses are likely to persist and further erode net worth, which already fell to Rs 335 crore in September from Rs 391 crore in March.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
High safety, with caution
Rated AA- by 2 agencies- ICRA expects things to get worse (negative outlook).
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| India Ratings | IND AA- | Stable | 10 Jun 2026 |
| ICRA | [ICRA]AA- | Negative | 24 Mar 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 10 Jun 2026 | Reaffirmed | IND AA- | — | India Ratings | ₹ 1 Cr. | |
| 24 Mar 2026 | Reaffirmed | [ICRA]AA- | — | ICRA | ₹ 993 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 26 Oct 2026 | Financial Results | To consider and approve the financial results for the Quarter and Half Year ended September 30, 2026 |
| 31 Jul 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 27 Apr 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 30 Jan 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 29 Oct 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 28 Jul 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 111 | 51 | 154 | 69 | 99 | 94 | 120 | 91 | 74 | 125 | 159 | 84 |
| Expenses | 114 | 69 | 141 | 116 | 118 | 100 | 114 | 102 | 80 | 121 | 149 | 84 |
| Operating Profit | −3 | −18 | 13 | −46 | −20 | −6 | 6 | −11 | −7 | 4 | 9 | −1 |
| OPM % | −3.1% | −36% | 8% | −67% | −20% | −6% | 4.6% | −12% | −9% | 3.2% | 6% | −0.8% |
| Other Income | 1 | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | −1 | 3 | 1 |
| Interest | 6 | 6 | 7 | 7 | 9 | 10 | 10 | 11 | 8 | 7 | 8 | 8 |
| Depreciation | 9 | 9 | 9 | 9 | 11 | 11 | 12 | 11 | 10 | 11 | 12 | 11 |
| Profit before tax | −18 | −32 | −1 | −62 | −39 | −25 | −16 | −33 | −24 | −16 | −8 | −19 |
| Tax % | −24% | −24% | 4% | −36% | 0% | 61% | 3% | 0% | 0% | 0% | −2% | 0% |
| Net Profit | −13 | −24 | −1 | −40 | −39 | −40 | −16 | −33 | −24 | −16 | −8 | −19 |
| EPS in Rs | −6 | −10.86 | −0.43 | −17.73 | −17.21 | −18.03 | −7.18 | −14.75 | −10.96 | −7.05 | −3.48 | −8.4 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 7%
- 5 Years
- −4%
- 3 Years
- −11%
- TTM
- 9%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- 50%
- 10 Years
- 4%
- 5 Years
- −14%
- 3 Years
- −23%
- TTM
- —
- 10 Years
- 2%
- 5 Years
- −8%
- 3 Years
- −26%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Astec LifeSciences | ₹ 599.50 | ₹ 1,480 Cr. | 110.6x | 3.8x | −25% | — |
| Asian Paints | ₹ 2,305.00 | ₹ 2,21,095 Cr. | 58.1x | 12.1x | 21.2% | 12.4% |
| Solar Industries India | ₹ 18,320.00 | ₹ 1,65,778 Cr. | 102.6x | 27.4x | 31.4% | 17.7% |
| Pidilite Industries | ₹ 1,514.00 | ₹ 1,54,107 Cr. | 64.8x | 14.7x | 23.8% | 16.9% |
| SRF | ₹ 2,309.00 | ₹ 68,444 Cr. | 44.5x | 6.1x | 13.8% | 11.6% |
| Linde India | ₹ 5,697.00 | ₹ 48,586 Cr. | 108.7x | 14x | 13.6% | 21.7% |
Management
- Deepak Jawaharlal Ochani
- Chief Financial Officer
- Arijit Mukherjee
- Chief Operating Officer, Executive Director
- Tejashree Rohan Pradhan
- Compliance Officer, Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.